Lipoproteins and Atherogenesis: Current Concepts

JAMA: The Journal of the American Medical Association

Volumn 264, Issue 23, 1990, Pages 3047-3052

  Steinberg, Daniel ^a   Witztum, Joseph L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; PRIORITY JOURNAL; REVIEW;

ARTERIOSCLEROSIS; HUMAN; LIPOPROTEINS; LIPOPROTEINS, LDL CHOLESTEROL; LIPOPROTEINS, VLDL CHOLESTEROL;

EID: 0025633323     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1990.03450230083034     Document Type: Article

References (91)

1. NIH Consensus Conference. Lowering blood cholesterol to prevent heart disease. JAMA. 1985;253:2080-2086.
2. Report on the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-69.
3. Steinberg D. The cholesterol controversy is over: why did it take so long? Circulation. 1989;80:1070-1078.
4. Tyroler HA. Lowering plasma cholesterol levels decreases risk of coronary heart disease: an overview of clinical trials. In: Steinberg D, Olefsky JM, eds. Hypercholesterolemia and Atherosclerosis. New York, NY: Churchill Livingstone Inc; 1987: 99-116.
5. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
6. Witztum JL. Current approaches to drug therapy for the hypercholesterolemic patient. Circulation. 1989;80:1101-1114.
7. Piper J, Orrild L. Essential familial hypercholesterolemia and xanthomatosis: follow-up study of twelve Danish families. Am J Med. 1956;21:34-46.
8. Mahley RW. Development of accelerated atherosclerosis: concepts derived from cell biology and animal model studies. Arch Pathol Lab Med. 1983;107:393-399.
9. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
10. Gordon DJ. HDL and coronary heart disease: a comparison of recent epidemiologic and clinical trial results. In: Miller NE, ed. High Density Lipoproteins and Atherosclerosis II. New York, NY: Elsevier Science Publishing Co Inc; 1989:3-10.
11. Carlson LA, Böttiger LE. Risk factors for ischemic heart disease in men and women. Acta Med Scand. 1985;218:207-211.
12. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med. 1976;295:369-377, 420-425.
13. Stemerman MB, Ross R. Experimental arteriosclerosis, I: fibrous plaque formation in primates, an electron microscopic study. J Exp Med. 1972;136:769-789.
14. Moore S. Thromboatherosclerosis in normolipemic rabbits: a result of continued endothelial damage. Lab Invest. 1973;29:478-487.
15. Ross R, Glomset J, Kariya B, et al. A plateletdependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA. 1974;71:1207-1210.
16. Poole JCF, Florey HW. Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits. J Pathol Bacteriol. 1958;75:245-251.
17. Davies PF, Reidy MA, Goode TB, Bowyer DE. Scanning electron microscopy in the evaluation of endothelial integrity of the fatty lesion in atherosclerosis. Atherosclerosis. 1976;25:125-130.
18. Fowler S, Shio H, Haley NJ. Characterization of lipid-laden aortic cells from cholesterol-fed rabbits, IV: investigation of macrophage-like properties of aortic cell populations. Lab Invest. 1979;41:372-378.
19. Gerrity RG, Naito HK, Richardson M, Schwartz CJ. Dietary induced atherogenesis in swine. Am J Pathol. 1979;95:775-792.
20. Aquel NM, Ball RY, Waldman H, Mitchinson MJ. Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis. 1984;53: 265-271.
21. Steinberg D. Lipoproteins and atherosclerosis: a look back and a look ahead. Arteriosclerosis. 1983;3:283-301.
22. Ross R. The pathogenesis of atherosclerosis— an update. N Engl J Med. 1986;314:488-500.
23. Steinberg D. Metabolism of lipoproteins and their role in the pathogenesis of atherosclerosis. In: Stokes J III, Mancini M, eds. Atherosclerosis Reviews. 1988;18:1-23.
24. Stary HC, Malinow MR. Ultrastructure of experimental coronary artery atherosclerosis in cynomolgus macaques: a comparison with lesions of other primates. Atherosclerosis. 1982;43:151-175.
25. Stary HC. Macrophages, macrophage foam cells, and eccentric intimal thickening in the coronary arteries of young children. Atherosclerosis. 1987;64:91-108.
26. McGill HC Jr. Questions about the natural history of human atherosclerosis. In: Glagov S, Newman WP III, Schaffer S, eds. Pathobiology of the Human Atherosclerotic Plaque. New York, NY: Springer-Verlag NY Inc; 1990:1-12.
27. McGill HC Jr. Fatty streaks in the coronary arteries and aorta. Lab Invest. 1968;18:560-564.
28. Small DM. Progression and regression of atherosclerotic lesions: insights from lipid physical biochemistry. Arteriosclerosis. 1988;8:103-129.
29. Gerrity RG. The role of the monocyte in atherogenesis, I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181-190.
30. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low-density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979;76:333-337.
31. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. NEngl J Med. 1989;320:915-924.
32. Mahley RW, Innerarity TL, Weisgraber KH, Oh SY. Altered metabolism (in vivo and vitro) of plasma lipoprotein after selective chemical modification of lysine residues of the apoproteins. J Clin Invest. 1979;64:743-750.
33. Fogelman AM, Schechter JS, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low-density lipoprotein leads to cholesterol accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A. 1980;77:2214-2218.
34. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low-density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low-density lipoproteins. Proc Natl Acad Sci U S A. 1981;78:6499-6503.
35. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low-density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984;81:3883-3887.
36. Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth muscle cells alter low-density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 1984;4:357-364.
37. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low-density lipoprotein previously incubated with cultured endothelial cells: recognition by receptor for acetylated low-density lipoproteins. Proc Natl Acad Sci U S A. 1981;78:6499-6503.
38. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low-density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest. 1987;74:1890-1894.
39. Cathcart MK, Morel DW, Chisolm GM III. Monocytes and neutrophils oxidize low-density lipoproteins making it cytotoxic. J Leukocyte Biol. 1985;38:341-350.
40. Parthasarathy S, Printz DJ, Boyd D, Joy L, Steinberg D. Macrophage oxidation of low-density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis. 1986;6:505-510.
41. Hiramatsu K, Rosen H, Heinecke JW, Wolfbauer G, Chait A. Superoxide initiates oxidation of low-density lipoprotein by human monocytes. Arteriosclerosis. 1987;7:55-60.
42. Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M. Type I macrophage scavenger receptor contains α-helical and collagen-like coiled coils. Nature. 1990;343:531-535.
43. Sparrow CP, Parthasarathy S, Steinberg D. A macrophage receptor that recognizes oxidized low-density lipoprotein but not acetylated low-density lipoprotein. J Biol Chem. 1989;264:2599-2604.
44. Arai H, Kita T, Yokode M, Narumiya S, Kawai C. Multiple receptors for modified low-density lipoproteins in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized low-density lipoproteins. Biochem Biophys Res Comm. 1989;159:1375-1382.
45. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low-density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372-1376.
46. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1989;10:336-349.
47. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84: 1086-1095.
48. Mitchinson MJ, Ball RY, Carpenter KLH, Parums DV. Macrophages and ceroid in atherosclerosis. In: Suckling KE, Groot PHE, eds. Hyperlipidaemia and Atherosclerosis. London, England: Academic Press; 1988:117-134.
49. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low-density lipoprotein. J Clin Invest. 1986;77:641-644.
50. Kita T, Nagano Y, Kokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1987;84:5928-5931.
51. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low-density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987;84:7725-7729.
52. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low-density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A. 1987;84:2995-2998.
53. Quinn MT, Parthasarathy S, Steinberg D. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low-density lipoprotein. Proc Natl Acad Sci U S A. 1985;82:5949-5953.
54. Hessler JR, Robertson AL Jr, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis. 1979; 32:213-219.
55. Henriksen T, Evensen SA, Carlander B. Injury to human endothelial cells in culture induced by low-density lipoproteins. Scand J Clin Lab Invest. 1979;39:361-368.
56. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low-density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134-5138.
57. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature. 1990;344:254-257.
58. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endotheliumdependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 1990; 344:160-162.
59. Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr. Interleukin-1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte lines. J Clin Invest. 1985;76:2003-2011.
60. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a new chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988;85:2805-2809.
61. Fogelman AM, Haberland ME, Seager J, Hokom M, Edwards PA. Factors regulating the activities of the low-density lipoprotein receptor and the scavenger receptor on human monocyte-macrophages. J Lipid Res. 1981;22:1131-1141.
62. Steinberg D. Arterial metabolism of lipoproteins in relation to atherogenesis. In: Lee KT, Onodera K, Tanaka K, eds. Atherosclerosis II: Recent Progress in Atherosclerosis Research. Ann N Y Acad Sci. 1990;598:125-136.
63. Gey KF, Puska P. Plasma vitamins E and A inversely correlated to mortality from ischemicheart disease in cross-cultural epidemiology. Ann N Y Acad Sci. 1989;570:268-282.
64. Salonen JT. Selenium in ischaemic heart disease. Int JEpidemiol. 1987;16:323-328.
65. Parthasarathy S, Khoo JC, Miller E, Barnett J, Witztum JL, Steinberg D. Low-density lipoprotein enriched in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci U S A. 1990; 87:3894-3898.
66. Goldstein JL, Ho YK, Brown MS, et al. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low-density lipoproteins. J Biol Chem. 1980;255:1839-1848.
67. Mahley RW, Innerarity TL, Brown MS. Cholesteryl ester synthesis in macrophages: stimulation by β-very low-density lipoproteins from cholesterol-fed animals of several species. J Lipid Res. 1980;21:970-980.
68. Koo C, Wernette-Hammond ME, Innerarity TL. Uptake of canine β-very low-density lipoproteins by mouse peritoneal macrophages is mediated by a low-density lipoprotein receptor. J Biol Chem. 1986;261:11194-11201.
69. Khoo JC, Miller E, McLoughlin P, Steinberg D. Enhanced macrophage uptake of low-density lipoprotein after self-aggregation. Arteriosclerosis. 1988;8:348-358.
70. Suits AG, Chait A, Aviram M, Heinecke JW. Phagocytosis of aggregated lipoprotein by macrophages: low-density lipoprotein receptor-dependent foam-cell formation. Proc Natl Acad Sci U S A. 1989;86:2713-2717.
71. Khoo JC, Miller E, McLoughlin P, Steinberg D. Prevention of low-density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. J Lipid Res. 1990;31:645-652.
72. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits, II: selective retention of LDL vs selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis. 1989;9:908-918.
73. Beaumont JL, Jacotot B, Beaumont V. L’hyperlipidémie par auto-anticorps: une cause d’athérosclerose. Presse Med. 1967;75:2315-2320.
74. Steinbrecher UP, Fisher M, Witztum JL, Curtiss LK. Immunogenicity of homologous low-density lipoprotein after methylation, ethylation, acetylation or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res. 1984;25:1109-1116.
75. Witztum JL, Steinbrecher UP, Kesaniemi YA, Fisher M. Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc Natl Acad Sci U S A. 1984;81:3204-3208.
76. Klimov AN, Denisenko AD, Vinogradov AG, et al. Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis. 1988;74: 41-46.
77. Hansson GK, Jonasson L, Seifert P, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis. 1989;9:567-578.
78. Geer JC. Fine structure of human aortic intimal thickening and fatty streaks. Lab Invest. 1965;14:1764-1783.
79. Burk JM, Ross R. Synthesis of connective tissue macromolecules by smooth muscle. Int Rev Connect Tissue Res. 1979;8:119-157.
80. Gerrity RG. The role of the monocyte in atherogenesis, II: migration of foam cells from atherosclerotic lesions. Am J Pathol. 1981;103:191-200.
81. Faggiotto A, Ross R. Studies of hypercholesterolemia in the nonhuman primate, II: fatty streak conversion to fibrous plaque. Arteriosclerosis. 1984;4:341-356.
82. Libby P. The active roles of cells of the blood vessel wall in health and disease. Molec Aspects Med. 1987;9:499-567.
83. Jonasson L, Holm, J, Skalli O, Bondjers G, Hansson G. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986; 6:131-138.
84. Masuda J, Ross R. Atherogenesis during low-level hypercholesterolemia in the nonhuman primate, I: fatty streak formation. Arteriosclerosis. 1990;10:164-177.
85. Masuda J, Ross R. Atherogenesis during low-level hypercholesterolemia in the nonhuman primate, II: fatty streak conversion to fibrous plaque. Arteriosclerosis. 1990;10:178-187.
86. Ross R, Masuda J, Raines EW, et al. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science. 1990;248:1009-1012.
87. Rubin K, Tingstrom A, Hansson GK, et al. Induction of β-type receptors for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular proliferative lesions. Lancet. 1988;1:1353-1356.
88. Libby P, Ordovas JM, Auger KR, Robbins AH, Birinyl LK, Dinarello CA. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol. 1986;124:179-186.
89. Libby P, Ordovas JM, Birinyl LK, Auger KR, Dinarello CA. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest. 1986;78:1432-1438.
90. Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, et al. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low-density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci U S A. 1990;87:6959-6963.
91. Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, et al. Gene expression in macrophage-rich human atherosclerotic lesions: 15-lipoxygenase and acetyl LDL receptor mRNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest. In press.